Fulminant Colitis



Mr Rowan Collinson FRACS



General surgery

Clinical

Collaborative

Timely intervention



'Fulminant colitis' ≈ Acute severe UC

= Absolute indication for surgery



Acute colitis

'Surgical colitis'

Surgery



Patient A

26 yr female

- Acute diarrheal illness
 - Now bloody
 - Abdominal pain
 - Bowel urgency
 - Frequency 8 x day



Acute colitis

- Infectious
 - Bacterial
 - Campylobacter
 - Shigella
 - Salmonella
 - Yersinia
 - Enterotoxigenic E. coli
 - Clostridioides
 - Parasitic
 - Entameba histolytica (amoebic)
 - Cryptosporidium
 - Viral
 - CMV

- Inflammatory
 - Ulcerative colitis
 - Crohn's disease
- Ischaemic colitis
- Microscopic colitis



GASTROINTESTINAL PCR (FilmArray) PANEL

RESULTS

Campylobacter : Not detected

C. difficile (toxin A/B) : Not detected

Plesiomonas shigelloides : Not detected

Salmonella : Not detected

Vibrio : Not detected

Yersinia enterocolitica : Not detected

E. coli (STEC) : Not detected

Shigella/ E. coli (EIEC) : Not detected

Cryptosporidium : Not detected

Cyclospora cayetanensis : Not detected

Entamoeba histolytica : Not detected

Giardia lamblia : Not detected

Adenovirus F 40/41 : Not detected

Astrovirus : Not detected

Norovirus GI/GII : Not detected

Rotavirus A : Not detected

Sapovirus : Not detected



Assessment

- Hx
- Exam
- Blood/urine analysis
- AXR
 - Consider cross-sectional
- Fluid resuscitation
- Stool cultures/PCR
- Medical review

Are there any of the following:

- Severe illness
 - Fever ≥38.5°C (101.3°F)
 - Signs or symptoms of hypovolemia
 - ≥6 unformed stools per 24 hours
 - Severe abdominal pain
 - Need for hospitalization
- High-risk host features
 - Age ≥70 years
 - Serious comorbidities, such as cardiac disease, immunocompromising condition (including advanced HIV infection)








More history available

Flexi sig done



- 4 days IV hydrocortisone 200mg BD
- Diarrhea 7 x day
- Fever 38.2



Assessment of severity

Estimate of likelihood of successful medical management

Presence of absolute indication for surgery



Assessment of severity

Defined by Truelove and Witts criteria

BRITISH MEDICAL JOURNAL

LONDON SATURDAY OCTOBER 29 1955

CORTISONE IN ULCERATIVE COLITIS

FINAL REPORT ON A THERAPEUTIC TRIAL


BY

S. C. TRUELOVE, M.D., M.R.C.P. AND L. J. WITTS, M.D., F.R.C.P.

Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford







FIRST ATTACKS RELAPSES Cortisone Cortisone Control Control Group Group Group Group 100 r 90 80 70 60 50 40 30 20 10 DEAD ALIVE, but with symptoms SYMPTOM-FREE throughout Fig. 4.—Position nine months

after trial period.



Table 1.2. Disease	e activity in U	C [adapted from Moderate 'in between n and severe'	Truelove & Witts ³²]. Severe
Bloody stools/day	< 4	4 or more if	≥ 6 and
Pulse	< 90 bpm	≤ 90 bpm	> 90 bpm <i>or</i>
Temperature	< 37.5°C	≤ 37.8°C	> 37.8°C or
Haemoglobin	> 11.5 g/dl	≥ 10.5 g/dl	< 10.5 g/dl or
ESR	< 20 mm/h	≤ 30 mm/h	> 30 mm/h <i>or</i>



Surgery, and Ileo-anal Pouch Disorders





Endoscopic Assessment of Disease Activity		Mayo Score	Endoscopic Features
	0	0	Normal
	1-3	1	Erythema, decreased vascular pattern, mild friability
	4-6	2	Marked erythema, absent vascular pattern, friability, erosions
	7-8	3	Spontaneous bleeding, ulceration

ACG Clinical Guideline: Ulcerative Colitis in Adults

David T. Rubin, MD, FACG¹, Ashwin N. Ananthakrishnan, MD, MPH², Corey A. Siegel, MD, MS³, Bryan G. Sauer, MD, MSc (Clin Res), FACG (GRADE Methodologist)⁴ and Millie D. Long, MD, MPH, FACG⁵






Table 4. Proposed American College of Gastroenterology Ulcerative Colitis Activity Index^a

	Remission	Mild	Moderate-severe	Fulminant		
Stools (no./d)	Formed stools	<4	>6	>10		
Blood in stools	None	Intermittent	Frequent	Continuous		
Urgency	None	Mild, occasional	Often	Continuous		
Hemoglobin	Normal	Normal	<75% of normal	Transfusion required		
ESR	<30	<30	>30	>30		
CRP (mg/L)	Normal	Elevated	Elevated	Elevated		
FC (µg/g)	<150-200	>150-200	>150-200	>150-200		
Endoscopy (Mayo subscore)	0–1	1	2–3	3		
UCEIS	0–1	2–4	5–8	7–8		
Modified from reference 44						


Modified from reference 44

The above factors are general guides for disease activity. With the exception of remission, a patient does not need to have all the factors to be considered in a specific category.

CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FC, fecal calprotectin; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.

ACG Clinical Guideline: Ulcerative Colitis in Adults

David T. Rubin, MD, FACG¹, Ashwin N. Ananthakrishnan, MD, MPH², Corey A. Siegel, MD, MS³, Bryan G. Sauer, MD, MSc (Clin Res), FACG (GRADE Methodologist)⁴ and Millie D. Long, MD, MPH, FACG⁵





'Fulminant colitis'

Absolute indications for colectomy

- Toxic megacolon
 - Total or segmental colon diameter >5.5cm
- Perforation
- Haemorrhage
- Multiorgan dysfunction





Predicting outcome in severe ulcerative colitis

S P L Travis, J M Farrant, C Ricketts, D J Nolan, N M Mortensen, M G W Kettlewell, D P Jewell

Gut 1996; 38: 905-910

- 'Travis criteria'
 - By day 3
 - Stool frequency >8
 - Stool frequency 3 8 and CRP >45



85 % require colectomy





Table 8. Poor prognostic factors in ulcerative colitis disease severity

Poor prognostic factors

Age <40 yr at diagnosis

Extensive colitis

Severe endoscopic disease (Mayo endoscopic subscore 3, UCEIS ≥ 7)

Hospitalization for colitis

Elevated CRP


Low serum albumin

The greater the number of poor prognostic factors, the worse the prognosis as measured by the likelihood of colectomy (4).


CRP, C-reactive protein; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.

ACG Clinical Guideline: Ulcerative Colitis in Adults

David T. Rubin, MD, FACG¹, Ashwin N. Ananthakrishnan, MD, MPH², Corey A. Siegel, MD, MS³, Bryan G. Sauer, MD, MSc (Clin Res), FACG (GRADE Methodologist)⁴ and Millie D. Long, MD, MPH, FACG⁵









Infliximab or cyclosporine

- CONSTRUCT trial IFX versus CSA
 - 'Colectomy-free survival rate'
 - 70% at 1 year
 - 60% at 5 years

Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): A mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol 2016;1:15–24.



Other preop surgical considerations

Ensure C.diff (toxin) and CMV colitis (flexi sig and biopsies) have been ruled out

Avoid NSAIDs, opiates and anticholinergic agents

DVT prophylaxis

Broad spectrum antibiotics

NO

YES

TPN for 'bowel rest'

- NO

EN with supplementation

- YES



Surgery - planning


Stoma education and marking

Positioning

Incision/access




Emergency total colectomy with end ileostomy



- Omentum
- Ileocolic artery
- Mesentery division
- Rectosigmoid division



Rectal stump



- Divided end and transanal rectal catheter
- Subcutaneous buried stump
- Sigmoid mucous fistula



Complications


Mortality

~2%

Morbidity

- 40-50%
- Wound infections/dehiscence
- Intra-abdominal abscess
- SBO
- Stoma complication
- Medical
 - Chest infection
 - DVT/PE
 - Portomesenteric venous thrombosis








Clostridium difficile colitis ('Clostridioides')

- Antibiotic association versus community acquired
- Over 300 toxigenic strains in Nth Am

- Diagnosis
 - Diarrhea > 3 times in 24hrs
 - Positive stool test for C. diff or pseudomembranes on lower endoscopy
- Only test stool if liquid









C. Diff severity grading

Table 2 Severity grading scale	- American college of gastroenterology. 16		
Mild	Moderate	Severe	Complicated
Diarrhea only	Diarrhea Any additional sign or symptom not meeting Severe or Complicated criteria	Diarrhea WBC>15,000 cells/μL Serum albumin <3 g/dL Abdominal tenderness	Any of the following: Hypotension (with or without vasopressor use) End organ failure Altered mental status Fever >38.5° Ileus or abdominal distention or tenderness WBC>35,000 cells/µL Serum lactate >2.2 mmol/L Admission to the ICU

Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis.* 2007;45:302—307.



Medical treatment

- Metronidazole
- Vancomycin

- FMT
 - Faecal microbiota transplant
- Mabs
- Immunoglobulin






Fig 5. Surgical consultation and treatment strategies for CDI. (From Brian S. Zuckerbraun MD, University of Pittsburgh.)



'Fulminant colitis' Absolute indications for colectomy

- Toxic megacolon
 - Total or segmental colon diameter >5.5cm
- Perforation


- Abdominal compartment syndrome
- Multiorgan dysfunction



Surgical strategies

Subtotal colectomy and end ileostomy

Diverting loop ileostomy and antegrade colonic lavage



- Creation of diverting loop ileostomy.
- Intraoperative antegrade colonic lavage with 8 liters of warmed PEG3350/electrolyte solution via ileostomy.
- Postoperative antegrade colonic enemas with vancomycin (500 mg in 500 mL X 10 days) via ileostomy.



OPERATIVE MANAGEMENT STRATEGY FOR CDAD




Fig 6. Operative management strategy for CDI. (From Brian S. Zuckerbraun MD, University of Pittsburgh.)

Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated *Clostridium difficile* associated disease. Ann Surg 2011;254:423-7; discussion 427-9.



Summary

General surgery

Clinical

Collaborative

Timely intervention

